Weekly selinexor, bortezomib, and dexamethasone (SVd) versus twice weekly bortezomib and dexamethasone (Vd) in patients with multiple myeloma (MM) after one to three prior therapies: Initial results of the phase III BOSTON study.

Details

Request a copyRequest a copy
Serval ID
serval:BIB_6A44DBAC3BD9
Type
Inproceedings: an article in a conference proceedings.
Publication sub-type
Abstract (Abstract): shot summary in a article that contain essentials elements presented during a scientific conference, lecture or from a poster.
Collection
Publications
Institution
Production externe
Title
Weekly selinexor, bortezomib, and dexamethasone (SVd) versus twice weekly bortezomib and dexamethasone (Vd) in patients with multiple myeloma (MM) after one to three prior therapies: Initial results of the phase III BOSTON study.
Title of the conference
Journal of Clinical Oncology
Author(s)
Dimopoulos MA, Delimpasi S., Simonova M., Spicka I., Pour L., Kryachok I., Gavriatopoulou M., Pylypenko H., Auner HW, Leleu X., Doronin V., Kaplan P., Hajek R., Reuben B., Dolai TK, Sinha DK, Arazy M., Richardson PG, Bahlis N., Grosicki S.
Organization
Annual Scientific Meeting of the American-Society-of-Clinical-Oncology (ASCO)
Address
ELECTR NETWORK
ISSN
0732-183X
Publication state
Published
Issued date
20/05/2020
Volume
38
Number
15
Pages
S
Language
english
Web of science
000560368303287
Create date
02/12/2024 17:49
Last modification date
13/12/2024 10:08
Usage data